IDH1 and acute myeloid leukemia: Nevertheless, the approved combination of IVO plus AZA in IDH1-mutated AML demonstrates a median OS of 24 months, an event-free survival (EFS) of 37% at 12 months, a CRc rate of 53%, along with a median duration of response of 22.1 months (22).